Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29012388 | 1.00 | IDO1 (0.50) | IDO1RAB9AHTR2AALDH1A1AKR1C3 | |
| SCHEMBL11412611 | 0.99 | IDO1 (0.51) | IDO1RAB9AHTR2AALDH1A1AKR1C3 | |
| SCHEMBL8229408 | 0.99 | IDO1 (0.51) | IDO1RAB9AHTR2AALDH1A1AKR1C3 | |
| Bromide SCHEMBL28819964 | 0.89 | IDO1 (0.50) | IDO1RAB9AHTR2AALDH1A1AKR1C3 | |
| Bromide SCHEMBL28819963 | 0.89 | IDO1 (0.50) | IDO1RAB9AHTR2AALDH1A1AKR1C3 | |
| SCHEMBL27769197 | 0.86 | IDO1 (0.50) | IDO1RAB9AHTR2AALDH1A1AKR1C3 | |
| SCHEMBL8350753 | 0.85 | RAB9A (0.52) | IDO1RAB9AHTR2AALDH1A1AKR1C3 | |
| SCHEMBL10500167 | 0.84 | IDO1 (0.54) | IDO1RAB9AHTR2AALDH1A1AKR1C3 | |
| SCHEMBL7275342 | 0.83 | HTR2A (0.53) | IDO1RAB9AHTR2AALDH1A1AKR1C3 | |
| SCHEMBL12214491 | 0.83 | HTR2A (0.53) | IDO1RAB9AHTR2AALDH1A1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-19 | — | — | US | disclosed |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| CN-116059390-A | Prodrugs of cytotoxic actives with enzymatically cleavable groups | 拜耳制药股份公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-02-09 | — | — | US | disclosed |
| EP-1423137-B1 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARM INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7335726-B2 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7262268-B2 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
| EP-1423137-A4 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARM INC (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1423137-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | Cubist Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030096948-A1 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | ADOLOR CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2003017924-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARMACEUTICALS, INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | IDO1 4187/4885RAB9A 1973/4885HTR2A 4730/4885 |
| US-20030096948-A1 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | LSS, NGLY1, RPN1 | IDO1 3163/4885RAB9A 2644/4885HTR2A 3669/4885 |
| US-20240043379-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | IDO1 4187/4885RAB9A 1973/4885HTR2A 4730/4885 |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | NGLY1, LSS, NRDC | IDO1 3113/4885RAB9A 2826/4885HTR2A 3531/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | IDO1 4518/4885RAB9A 1701/4885HTR2A 4578/4885 |
| US-12144865-B2 | Antibody drug conjugates with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | IDO1 4423/4885RAB9A 557/4885HTR2A 4702/4885 |
| US-20230039341-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | IDO1 4164/4885RAB9A 572/4885HTR2A 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.